Abstract | The ability of the human kidney to repair itself is limited. Consequently, repeated injury can trigger a maladaptive response that is characterized by fibrosis and loss of renal function. The transcription patterns that characterize nephrogenesis in fetal renal progenitor cells (RPCs) are only partially activated during renal repair in adults. Nevertheless, evidence suggests that segment-restricted progenitor resident cells support renal healing in adults. In this Review, we discuss the evidence for the existence of functional human RPCs in adults and their role in renal repair, and consider the controversial issue of whether RPCs are a fixed population or arise through phenotypical plasticity of tubular cells that is mediated by the microenvironment. We also discuss the strategies for generating renal progenitor cells from pluripotent stem cells or differentiated cells and their use in therapy. Finally, we examine preclinical data on the therapeutic use of human fetal cells, adult progenitor cells and adult renal cells.
Introduction
Kidney disease is now considered to be a research and public health priority, owing to its increasing worldwide incidence and associated morbidity and mortality. 1 Acute kidney injury (AKI) is characterized by an acute loss of kidney cells and function that results from ischaemic, toxic or inflammatory insults. The condition is associated with an increased risk of in-hospital morbidity and mortality, despite supportive therapy. 1 In addition, progressive loss of nephrons can result from repeated acute insults or chronic injury, leading to the requirement for renal replacement therapy.
The development of acute and chronic renal disease might depend on impaired renal repair that prevents a regain of function. Neonephrogenesis does not occur in the adult human kidney, but the kidney does retain some regenerative potential. Evidence from several studies suggests that repair processes in adult kidneys involve resident nephron cells that survive injury and have a dedifferentiated phenotype with clonal proliferative potential. 2, 3 However, during adult kidney repair, these cells express only part of the transcription pattern that is seen in fetal renal progenitor cells (RPCs) and characterizes nephron generation, indicating differences in the mechanisms and weaknesses of the repair process. 4 Consequently, repair in adult tissue is limited; repeated injury therefore results in a maladaptive response, leading to fibrosis and loss of function. Indeed, the fact that patients with AKI or subclinical graft rejections can develop chronic kidney disease (CKD) is well established. 5 CKD is also characterized by a loss of regenerative processes.
Here, we review the current knowledge of the existence of RPCs in renal tissue, and the isolation and in vitro generation of such cells. We focus on studies performed in human tissue, and discuss the potential therapeutic applications of RPCs.
Progenitor-like cells in renal tissue
The fetal kidney In all mammals, development of mature nephrons involves differentiation and organization of mesenchymal RPCs. In the embryonic metanephros, reciprocal inductive interactions between the metanephric mesenchyme and the ureteric bud are required for kidney formation. 6 These interactions transform mesenchymal progenitor cells into kidney structures, leading to organization of the nephron. The cap mesenchyme is the niche in which RPCs undergo the transition from mesenchymal to epithelial cells. 7, 8 These committed progenitor cells then sequentially form pretubular aggregates, renal vesicles, C-shaped bodies and S-shaped bodies that develop into the glomerular and renal tubule compartments. 6 The embryonic progenitor cells are the prototypes of the renal cell population that can proliferate and differentiate into different types of nephron epithelia, and defining the cellular mechanisms that are involved in their function could therefore provide insight into the mechanisms of renal regeneration in adults. Several markers of RPCs, such as transcription factors, in the developing kidney have been identified, mostly in mouse studies. RPCs in the mouse embryo were first characterized as a multipotent population with self-renewing capability that express homeobox protein SIX2 (SIX2). 8 Fate mapping in the mouse embryo led to the identification of several markers of progenitor cell maintenance www.nature.com/nrneph and differentiation, 9 including Sal-3, 10 Eya1, 11 Osr1 12 and Cited1, 7 as well as Pax2 13 and Wt1, 14 which are both transcription factors. Other markers that were identified are involved in segment specification: the Wnt signalling target Lgr5 is responsible for generating the thick ascending limb of the loop of Henle and the distal convoluted tubule, 15 and Notch 2 seems to regulate the shift from self-renewal to differentiation, thereby specifying proximal tubules. 16 Human fetal RPCs have not been so well characterized. An extensive analysis of gene expression in Wilms tumour, which is characterized by loss of terminal progenitor differentiation, identified a number of genes involved in progenitor differentiation. 17 A cell population that expresses known markers of fetal renal progenitor cells-SIX2, WT1, CITED1, and Sal-1-was shown to coexpress NCAM-1 and FzE3, indicating that the expression of these two genes is also a marker of RPCs. 18 By contrast, CD133 seems to be expressed by cells that express epithelial cell adhesion molecule (Ep-CAM, a marker of cell differentiation), indicating that CD133 is a marker of cells with a more differentiated phenotype than that of mesenchymal RPCs. 18 NCAM-1 and CD133 have been successfully used to isolate RPCs from the fetal renal kidney. 19 NCAM-1 is absent from the normal adult human kidney, whereas CD133 is expressed from the vesicle stage onwards 20, 21 and is retained in unevenly distributed cells, commonly referred to as scattered cells, in adult renal tissue. 3, 22 The nephrogenic mesenchymal progenitor cell population does not remain in the adult kidney, possibly owing to the loss of its niche. 23 In humans, RPCs are only induced in the nephrogenic pathway until the 34 th week of gestation, 19 and no equivalent cell types exist in the adult kidney. Even during renal repair, only partial fetal transcriptional patterns are observed; markers expressed include PAX2, BMI1 and SIX2. 4, 24 RPCs in the adult kidney Whole nephron regeneration is not possible in the human adult kidney, but organ homeostasis and repair Key points ■ Embryonic renal progenitor cells (RPCs) represent the prototype of the kidney cell population with nephrogenic potential, but the nephrogenic mesenchymal progenitor population is absent in the adult human kidney ■ In adults, RPCs seem to be segment-restricted, and several studies indicate that these cells arise through phenotypic plasticity of tubular cells; CD133 + cells with progenitor-like properties exist in all human nephron segments ■ Adult human RPCs obtained from different nephron segments or urine show therapeutic potential in acute tubular and glomerular damage, through paracrine mechanisms and differentiation ■ Adult and fetal RPCs show engraftment in glomeruli and tubules in preclinical models of chronic kidney disease; generation of patient-derived RPCs could enable autologous therapy that does not require immunosuppression ■ Intraparenchymal injection of differentiated adult renal cells seems to be beneficial in chronic kidney disease ■ The administration route of RPCs in cell therapy must be defined; tubular localization requires RPCs to passage through basal membranes, so local administration seems more feasible require cells with progenitor-like characteristics. These progenitor-like cells are required for continuous replacement of cells that are lost during physiological processes: ~6,000 cells from different nephron segments are lost every hour and excreted in the urine. 25 In addition, repair after AKI requires repopulation of tubular compartments. Initial stem cell studies supported the hypothesis that residual stem cells are involved in these processes, whereas subsequent studies failed to identify multipotent cells with the ability to generate nephrons.
Mouse studies
Fate mapping and cell lineage tracing have been used to investigate the presence of RPCs and their role in renal regeneration in mice. The involvement of nephronresident cells in tubule regeneration was first demonstrated in 2008 by fate mapping: genetic labelling of mesenchyme-derived renal epithelial cells excluded a role of stem cells from the interstitium or bone marrow in renal repair after acute injury. 26 In 2014, lineage tracing of differentiated tubular cells after acute ischaemic damage revealed clonal proliferation of tubular epithelial cells. 27 Expansion of single proximal tubule clones also contributed to tubule elongation during nephrogenesis and kidney growth. 27 These results were attributed to proliferation of all cells within a specific tubular segment, but do not exclude the possibility that a subpopulation of cells with progenitor properties proliferate and repair the tubular segments. Indeed, subsequent cell lineage tracing in so-called rainbow mice, which express multicoloured reporter constructs, showed that cells with segment-specific clonogenic and proliferative potential can support renewal of kidney epithelia throughout life. 2 Cell colonies that expressed only one colour were detected in kidney segments 6 months after cell tagging, indicating the presence of cloneforming cells.
2 Clonogenic segment-specific cells also contributed to the repair of specific nephron segments, suggesting that nephron regeneration can be mediated by segment-committed clonogenic RPCs.
Together, these observations indicate that regeneration of renal tubules relies on a functional population of RPCs. Nevertheless, the identity of these cells remains elusive, and they could either derive from a predetermined population of RPCs or develop when differentiated cells transiently acquire an RPC phenotype.
One 2014 study identified and labelled a subpopulation of proximal tubular cells (so-called scattered tubular cells) that increased in number during ischaemic injury. 28 These data do not exclude concomitant activation of RPCs, but demonstrate that differentiated tubular cells can acquire a progenitor-like function, and suggest that plasticity of the tubular phenotype is involved in regeneration. 29 Regenerative potential in the glomeruli is limited relative to that in the tubules. RPCs that were identified in the Bowman capsule were initially thought to contribute to podocyte regeneration, as they migrated into the glomerular tuft during infancy and adolescence, 30 but this process was not observed in adults. 31 Intratubular populations of slow-cycling cells that retain proliferative labels (a property of progenitor and stem cells) have been found in proximal and distal tubules, the thick ascending limb of the loop of Henle, 32 and in the papilla. 33 Furthermore, specific populations of progenitor cells have been identified in proximal tubules through their expression of stem-cell markers: NFATc1 in proximal tubules, 34 and Lgr5 or CD117 (c-Kit) in the thick ascending limb of the loop of Henle and the distal convoluted tubules. 15, 35 Distinct populations of segmentspecific progenitor cells might be characterized by the expression of different markers (Table 1) .
Human studies
In human tissue, a discrete population of cells that express CD133-a glycosylation-dependent epitope of prominin that is detectable with the AC133 antibody and expressed by haemopoietic stem cells 36, 37 -was detected in the Bowman capsule, the proximal and distal tubules, and the inner medullary papilla region, including the loop of Henle and the S3 limb segment (Table 1) . [38] [39] [40] [41] [42] [43] [44] [45] In the Bowman capsule, CD133 + CD24 + cells localized at the tubular pole, in contrast to cells that expressed podocyte differentiation markers, which localized to the vascular pole. 43 In proximal tubules, CD133 + cells were mainly located in the tubular plicae, where proximal convoluted tubules make hairpin turns. 3, [39] [40] [41] [42] [43] [44] In the distal nephron, small clusters of CD133 + CD24 + cells were detected in the portion of the distal convoluted tubule that makes contact with the vascular pole of the glo merulus. 44 The markers that were coexpressed in CD133 + cells varied according to the localization of the cells (Figure 1 ). In particular, CD133 + cells in the Bowman capsule and proximal tubule coexpressed the mesenchymal markers vimentin, cytokeratin-7 and cytokeratin-19, which are not expressed by most tubular epithelial cells (Figure 1 ). [40] [41] [42] Most studies of CD133 + cells have been performed on normal kidney specimens from patients with tumours, which has led to the suggestion that CD133 + cells do not pre-exist but are induced by tubular injury. CD133 + cells (3-12% of all cells observed) have also been found in normal pretransplantation renal biopsy specimens from native donors of all ages, indicating that the presence of these cells is normal. 3 However, this result conflicts with the observation that scattered tubular cells are absent in normal juvenile rodents. 40 Electron microscopy of scattered intratubular cells indicates a striking difference in their morphology when compared with adjacent normal proximal tubular cells: the scattered cells are smaller, lack brush border microvilli and have fewer mitochondria. 40 The lack of mitochondria has been confirmed by the use of gold-conjugated vimentin antibodies with electron microscopy, and by double immunofluorescence staining of renal tissue for CD133 and mitochondrial markers.
3 CD133 has a role in glucose uptake, 45, 46 so an anaerobic metabolism in the CD133 + population could explain their ability to survive after injury. 3 Indeed, one study showed that CD133 inhibits endocytosis of the transferrin receptor, thereby inhibiting iron uptake and, consequently, mitochondrial activity.
45
CD133 expression has also been related to glucose uptake in glioma cells. 46 Furthermore, in an explant model in which human renal tissue was subjected to ischaemiareperfusion damage, the CD133 + scattered cells that expressed vimentin, cytokeratin-7 and cytokeratin-19 did not undergo necrosis and remained anchored to the basal membranes; cells that detached were negative for these markers. 3 This observation supports the notion of a physiologically distinct cell population that has high resistance to damage owing to a possible role of CD133 in glycolytic metabolism, rather than the notion of an injury-induced cell population. It does not address, however, whether CD133 + cells are a fixed population or represent a transient functional state that is modulated by microenvironmental stimuli.
RPCs in renal pathology
Regardless of its origin, the CD133 + cell population seems to contribute to acute tissue repair of the tubular compartment. 3, 40, [47] [48] [49] By contrast, activation of this population in glomeruli seems to be associated with glomerular disease. 20 A study of patients who underwent kidney transplantation was the first to report that the number of CD133
+ cells was significantly greater in the transplants of patients in whom graft function was delayed by acute injury than in pretransplantation biopsy specimens of the grafts or in the transplants of patients with early graft function. 47 Three other studies reported abnormally high numbers of tubular CD133 + cells after acute tubular necrosis in patients who had received renal transplantation, or in proteinuric glomerular disease. 3, 40, 44 Involvement of these cells in renal repair is strongly supported by the evidence that almost all proliferating cells in acute tubular injury biopsy samples were CD133 + and CD24 + . 3, 40, 44 These cells also expressed the KIM-1 marker of injury. 40 Interestingly, the number of CD133 + cells in patients with acute tubular necrosis seems to be a predictive marker of tissue recovery. 48 The presence of cells that express progenitor markers has also been reported in chronic tissue injury. Stripes and clusters of proliferating CD133 + tubular cells were detected in biopsy samples from patients with chronic tubulointerstitial damage caused by urinary obstruction or focal segmental glomerulosclerosis (FSGS), suggesting activation of tissue repair mechanisms. 3, 44 An interesting question is whether loss of regenerative ability in chronically damaged human tissue could be the result of exhaustion of the CD133 + cell pool or of CD133 + cell senescence. Evidence from one study indicates that cell senescence is important. In this study, blocking the G2-M phase of the cycle was associated with development of a senescent secretory phenotype in tubular cells after repeated injury. 50 Progenitor-like cells with increased proliferative ability are also involved in the abnormal proliferation that underlies pathology. For example, these cells are found in the glomerular tuft during acute glomerulonephritides and in cysts in polycystic kidney disease. 20, 49, 51 Proliferation of CD133 + cells has also been reported in glomerular hypercellular lesions, in pseudo-crescents and in crescents that lead to obliteration of the Bowman space in collapsing glomerulopathy and crescentic glomerulonephritis, and within glomerular tip lesions at the tubular pole of the Bowman capsule. 20, 49 Similarly, in polycystic kidney disease, all cyst-lining cells strongly express CD133. 52 Studies in human renal tissue clearly indicate the existence, in all nephron segments, of cells that can be defined as adult RPCs according to a functional definition of progenitor cells, as they can proliferate, participate in tissue homeostasis and repair, and survive injury. Phenotypically, they also lack a differentiated phenotype and express stem-related markers. On this basis, a plausible hypothesis is that adult human CD133 + RPCs represent the same population as segment-restricted progenitor cells in mice. 2 Whether the progenitor phenotype of these cells is fixed or inducible is difficult to determine, however, as lineage tracing cannot be used in humans. However, cellular plasticity seems to be the most likely explanation. Evidence exists for such plasticity in the lung, 53 bone marrow 54 and pancreas, 55 and an increasing body of evidence supports the hypothesis that the stem and progenitor phenotype is dynamic, characterized by continuous cell cycling and regulated by microvesicle-related microenvironmental stimuli. 56 
RPC cultures
Most data on the phenotypical and functional characteristics of RPCs are based on their function and phenotype in culture. Many different RPCs from mice have been isolated according to their stem-related characteristics: marker expression, bromodeoxyuridine label retention, side population or clonogenicity, for example. 51, [57] [58] [59] [60] These cell lines showed variability in marker expression, site of origin, potency and ability to differentiate. More homogeneous results have been obtained in studies of human cells, using the strategies described below.
Isolation of RPCs from human renal tissue
In 2005, we isolated and characterized cells expressing the AC133-detectable CD133 stem cell marker from the human renal cortex. 61 In subsequent studies, CD133 + cells were isolated from the Bowman capsules of human glomeruli 38 and from the inner medulla. 39, 41 These CD133 + populations, although isolated from different nephron segments, all expressed fetal renal markers (including PAX2, WT1 and CD24) and several mesenchymal stem cell markers (including CD29, CD73 and CD90); minor variations in expression levels were observed, possibly owing to differences in cell culture conditions. These findings were confirmed by a gene expression profile, which clustered together CD133 + cells from glomeruli and tubules against differentiated epithelial cells. 62 However, some proteins were differentially expressed among the CD133 + cells, including VCAM-1 (also known as CD106), the expression of which was ~300-fold greater in CD133 + CD24 + cells from glomerular outgrowths than in cells from tubules. 44 Functionally, isolated CD133 + cells were clonogenic and most importantly, differentiated into tubular cells of different nephron segments or glomerular podocytes after appropriate stimulation. 38, 61 When injected into immunodeficient mice, the CD133 + cells also generated tubular structures and expressed nephron segment markers. + cells isolated from the inner medulla were shown to synthesize and release erythropoietin under conditions of hypoxia. 63 In combination, these findings identify CD133 + cells as RPCs. CD133 + cell cultures generated by cell sorting should represent the CD133 + population in renal tissue. However, total cell cultures of kidney cells can express CD133 at fairly high levels. 64 One possible explanation for this observation is a selective ability of CD133 + RPCs to survive in culture. Another is that CD133 expression could result from culture-induced dedifferentiation of cells. This second possibility has been excluded for podocytes that were isolated from urine, as these cells did not participate in the generation of CD133 + cells, 65 but remains a possibility for tubule-derived cell cultures. Regardless of the explanation, plasticity of cultured CD133 + RPCs might provide insights into mechanisms of kidney repair and could be exploited for renal regeneration.
Other selection strategies, based on functional assays, have been used to identify and isolate RPCs from human renal tissue. In one study for example, cells were sorted on the basis of an assay that evaluates the activity of aldehyde dehydrogenase, an enzyme that is overexpressed in stem cells. 42 Cells with high aldehyde dehydrogenase activity expressed CD133 and vimentin and had a similar appearance to CD133 + cells, further indicating the progenitor nature of CD133 + cells. 42 Another functional assay that is frequently used for stem cell isolation exploits the ability of these cells to form spheres as they grow in culture. The so-called nephrospheres contain cells at different levels of maturation, 66 and retention of the cell tracer PKH 26 by cells within nephrospheres enables identification of quiescent cells. One study that used this approach identified a self-renewing population of cells that were capable of differentiating into cells with epithelial, endothelial or podocytic characteristics. 66 Interestingly, these cells also had a CD133 +
CD24
-phenotype. A different approach exploited the expression of the fetal marker NCAM-1, which is induced in a fraction of human renal cells when they are placed in culture. 64 NCAM-1 is absent in normal adult renal tissue, but can be expressed again after ischaemia-reperfusion injury. 67 NCAM-1 + RPCs have a mesenchymal phenotype and are enriched with transcription factors (SIX2, Sal-1, PAX2, WT1 and Oct-4) that are markers of renal progenitor and stem cells. These cells also have characteristics of stemness, such as clonogenicity, an ability to form spheres and the potential for tubulogenic differentiation. 64 Research on cultured human renal RPCs is limited by the fact that all the described cell lines have a limited lifespan and become senescent over time. No robust, long-term culture system that maintains potent, clonal expansion of adult progenitor cells over long periods of time under defined conditions currently exists.
Isolation of RPCs from urine
Freshly voided urine and urine from the upper urinary tract contain multipotent stem cells, 68, 69 and CD133 + CD24 + RPCs have been isolated and cultured from the urine of healthy people and patients with kidney disorders. 65 The phenotypes and functions of urinederived RPCs are similar to those of tissue-derived RPCs, and the cells can differentiate into both tubular cells and podocytes. 65 Exploitation of the fact that fetal urine is released into the amniotic fluid has also led to successful isolation from this fluid of a subpopulation of metanephric mesenchyme-like cells that are committed to nephron lineages and capable of differentiating into podocytes. 70 Urine-derived CD133 + CD24 + RPCs have been used for the diagnosis of genetic glomerular disorders and to derive podocytes in vitro for functional analysis of potentially pathogenic mutations. 65 These cells have therefore emerged as a new research and diagnostic tool. 65 Urine-derived cells might also be an attractive source of autologous cells for cell therapy.
Mesenchymal stromal cells from renal tissue
Cells with a mesenchymal origin and multipotent properties exist adjacent to endothelial cells of the microvasculature, identifiable on the basis of marker expression (CD146, CSPG4, and CD140b), and might contribute to tissue support. 71 Renal mesenchymal stromal cells (MSCs) that were isolated from the mouse kidney differentiated into renin-producing cells in vitro and when they were injected into mice that were kept on a low-salt diet, 72 indicating that they are committed to becoming renal cell types. A study published in 2015 showed that cells isolated from adult mouse collecting ducts can generate MSC-like cells after long-term culture in vitro owing to the phenomenon of epithelial-to-mesenchymal transition. 73 The isolated cells give rise to a population of long-term selfrenewing MSCs with the capacity for pan-mesodermal differentiation. In addition, renal MSCs can integrate into aquaporin-2-positive medullary collecting ducts when injected into the kidneys of neonatal mice, unlike MSCs that derive from bone marrow. 74 Renal MSCs also express a specific pattern of genes-possibly related to a 'molecular memory' of tissue origin-that is not seen in MSCs from bone marrow, supporting the hypothesis that renal MSCs are committed to developing into renal tissue. 74 These findings suggest that renal MSCs have organspecific regenerative capacities that, for renal repair, are highly superior to those of MSCs from unrelated organs. This property of renal MSCs could, therefore, be exploited for therapeutic applications. 74 In human kidneys, resident glomerular MSCs have been characterized as CD133 -and CD146 + , clonogenic, able to self-renew, and able to differentiate into endothelial, mesangial or epithelial glomerular cells. 75 The presence of donor-derived MSCs in a kidney that had been transplanted to a sex-unmatched donor provides evidence that glomerular MSCs do not derive from the bone marrow. 75 
RPC phenotype plasticity
Microenvironmental stimuli for RPC modulation As described above, the nature of the cells that are involved in kidney homeostasis and regeneration is unclear, and further studies are required to define the mechanisms involved in their activation. 76 If the phenotype of RPCs is plastic, then activation of the progenitor phenotype could be a consequence of a specific cell cycle state or of external stimuli that modulate the growth and differentiation of resident cells. Evidence for cell reprogramming by the microenvironment has come from mouse studies in which soluble signals from a diseased kidney induced generation of scattered tubular cells with progenitor properties in the contralateral kidney. 27, 77 Knowledge of the mechanisms that modulate the RPC phenotype could be relevant to the development of therapeutic approaches, such as pharmacological approaches that modulate cells, or the ex vivo treatment of cells before their in vivo injection.
The phenotype of RPCs seems to be activated by hypoxia: in one study, hypoxia increased proliferation, clonogenicity and CD133 expression in RPCs that were isolated from the inner medulla. 39 Consistent activation of hypoxia-inducible factor 1 was seen in these RPCs. The mechanism by which hypoxia activates the progenitor phenotype might rely on hypoxia-induced expression of the stem cell transcription factor Oct-4 and its regulation by microRNA-145. 39 A comparative analysis of cortical RPCs and differentiated tubular cells identified two microRNAs that are involved in the regulation of RPC stemness and differentiation: miR-1915, which regulates the expression of the progenitor factors CD133 and PAX2, and miR-1225-5p, which regulates the expression of Toll-like receptor 2, an important gene that is involved in damage signalling and is upregulated in RPCs. 78 Wnt signalling has also been linked to RPC maintenance in mice: activity of this signalling pathway is increased in clonogenic renal cells. + metanephric mesenchyme progenitor cells. 80 Such advances in iPSC differentiation led to successful generation of entire renal structures 81 and renal organoids. 82 The generation of autologous cells with nephrogenic potential is highly promising for regenerative medicine of the kidney, although the tumorigenic potential of these cells and the scarce proliferation of cells that are differentiated from iPSCs still greatly limit this approach.
An alternative approach to the generation of RPCs is direct reprogramming of renal cells into progenitor cells. Sequential screening has been used to identify six genes (SIX1, SIX2, OSR1, EYA1, HOXA11 and SNAI2) whose expression reprogrammes human tubular cells to become metanephric mesenchymal progenitor cells. 83 The progenitor cells produced in this study contributed to the nephrogenic compartment of a developing embryonic kidney ex vivo. This study represents a huge step towards the generation of progenitor cells for use in vivo. However, transfection techniques must be optimized, including the use of nonintegrating or inducible vectors, and ideal growth conditions must be established before this approach can be used therapeutically.
RPCs in models of kidney injury
Cell therapy is the most promising tool for the regeneration of renal tissue (Figure 2) . In zebrafish, Nature Reviews | Nephrology transplantation of RPCs with nephrogenic potential generated multiple nephrons. 84 In fish, the mesenchymal nephron progenitor cell population persists into adulthood and supports de novo nephrogenesis. In humans, RPCs do not generate new nephrons, but might instead support nephron repair. If human metanephric mesenchymal nephron progenitor cells could be generated, they would enable the creation and integration of new nephrons.
Cell therapy with embryonic or fetal RPCs
Multiple studies have demonstrated the therapeutic potential of RPCs from fetal kidneys in acute and chronic renal injury. In mice with glycerol-induced AKI, injection of human fetal CD133 + CD24
+ RPCs improved renal function. 21 In this model, the effects of these cells were comparable to those of adult RPCs. 44, 61 In the 5/6 nephrectomy model of kidney injury-which is characterized by progressive loss of renal mass-human fetal nephron NCAM-1 + progenitor cells engrafted and integrated into diseased mouse kidneys when injected directly into the renal parenchyma. 19 Renal function consequently improved, and disease progression stopped.
Metanephric mesenchyme-like RPCs that are generated from iPSCs have also shown potential for differentiation in vitro and in vivo in the embryonic kidney. 81 In a 2015 study, RPCs that were derived from human iPSCs exhibited robust engraftment into damaged tubuli and restored renal function in a mouse model of AKI. 85 
Cell therapy with adult RPCs
Pioneering experiments in rat and mouse models of acute tubular or glomerular damage suggested a therapeutic effect of adult RPCs of different types and site of origin (Table 2) . 57,51,,60,86 Similarly, adult CD133 + CD24 + RPCs from the Bowman capsule, cortical tubular compartment and inner medulla had therapeutic effects in immunodeficient mice with rhabdomyolysis-induced AKI (Table 3) . 38, 44, 61, 87 In these studies, a single dose of CD133 + cells (5 × 10 5 -1 × 10 6 cells) was administered after renal damage had been induced. The cell therapy improved renal function: serum creatinine and urea levels dropped rapidly, and the histological appearance of tissue improved. 38, 44, 61, 87 These results correlate closely with those commonly obtained when MSCs are used therapeutically, and comparison of medulla-derived CD133 + cells with MSCs demonstrated an equivalent therapeutic effect. 87 However, a biodistribution study showed that, 48 h after injection, CD133 + cells preferentially localize to the kidney and exhibit less cell dispersion in other parenchymal organs than do MSCs. 87 Administration of CD133 + CD24 + cells that were isolated from the Bowman capsule improved renal outcomes in a model of FSGS that is characterized by podocyte injury; the therapy reduced proteinuria and ameliorated chronic glomerular damage. 43 This effect was only observed when undifferentiated CD133 + cells that were isolated from urine also differentiated into podocytes and reduced proteinuria in rats with adriamycin-induced nephropathy. 65 In one study, the therapeutic effects of NCAM-1 + RPCs that overexpress markers of fetal RPCs were compared with those of cultured human kidney epithelial cells that are uniformly CD133 + and CD24 + . In glycerol-induced AKI in mice, both cell types had a therapeutic effect, and no difference was seen between NCAM-1 + and NCAM-1 -cells. 64 This observation suggests that renal epithelial cells could be used for cell therapy (see below). Similarly, mature tubular epithelial renal-like cells, which were produced from the differentiation of spermatogonial-derived embryonic-like stem cells, protected against acute and chronic damage in vivo in a mouse model of kidney ischaemia. 88 Administration of human CD133
-cells was not beneficial for acute tubular or glomerular damage, 38, 43, 44 but the cell population was not fully characterized; whether the lack of therapeutic effect was related to activity of fibroblasts or of renal epithelial cells cannot, therefore, be determined.
Mechanisms of RPC action
An intriguing aspect of renal regenerative medicine is the mechanism by which administered cells exert their effect. The effect ascribed to MSCs is mainly related to the paracrine delivery of soluble mediators and bioactive vesicles that contain mRNA and microRNA, 89 whereas for human RPCs, mechanisms of both paracrine stimulation and tissue integration have been described. Some evidence suggests that RPCs contribute to tissue repair via paracrine signalling that involves the release of various growth factors and vesicles. In particular, IL-15-a kidney-specific factor that is involved in renal differentiation 90 -was selectively released by CD133 + cells and not by MSCs. 87 RPC-derived extracellular vesicles might also be involved in the process of repair, as they promoted in vitro survival and proliferation in target epithelial cells. 91 Evidence also exists for a role of RPC integration in tissue repair. Adult RPCs that were injected into the kidneys of mice with AKI were detectable in both proximal and distal tubules. 38, 44, 61 Analysis of cell integration after 11 days showed that ~7% of tubular cells coexpressed tubule markers and the dye with which RPCs were labelled, indicating that the RPCs had differentiated and integrated. 38 Similarly, in a mouse model of podocyte damage, CD133 + CD24 + PODXL -cells generated new podocytes; after 7 days, these new podocytes represented 11.08 ± 3.30% of the total number of podocytes and had maintained their engraftment after 45 days. 43 Interestingly, RPCs from the Bowman capsule could differentiate into podocytes or tubular cells, whereas RPCs from the tubule were restricted to tubular differentiation. 44 By contrast, RPCs that were isolated from the inner medulla exhibited limited persistence in murine tissue at 1 month after injection. 87 Fetal RPCs that were directly injected into the renal parenchyma of 5/6 nephrectomized kidneys also integrated efficiently. 19 Tissue analysis revealed that RPCs were initially located within either existing mouse tubules or the interstitium, and that after 3 months they tended to have formed epithelial tubules with a mature appearance and a patent lumen, a process that resembles segment nephrogenesis. 19 Data indicate that engraftment of adult RPCs within tubules is variable. 19, 44, 61, 87 Whether RPC engraftment in the kidney entirely accounts for repopulation of tubular cells is therefore questionable. To date, human RPCs have accounted for no more than 10-11% of cells within regenerating rodent tubules, and evidence for their differentiation into mature epithelial cells is weak. Dedicated long-term experiments are needed to determine the relevance of RPC integration, whereas, to date, most studies in models of both AKI and CKD have assessed engraftment after only 2-4 weeks. We suggest that a combined mechanism of paracrine support and integration is responsible for the effects of RPCs that have been observed in preclinical studies. A reasonable hypothesis is that engrafted RPCs coordinate endogenous repair.
Alternatively, a paracrine mechanism, such as that described for MSCs, 89 could be sufficient for a therapeutic effect. This hypothesis was confirmed for kidneyderived MSCs, as the therapeutic effects of the cells were recapitulated by administration of only extra cellular vesicles that were derived from kidney MSCs. 92, 93 In acute damage, activation of resident responsive regenerative cells could be sufficient to support repair, but these resident cells could be lost in CKD so that integration of new functional cells is required. In the setting of acute injury, therapy with MSCs therefore seems to be more clinically applicable than with RPCs, particularly because sources of RPCs are limited, tissue from which autologous RPCs can be obtained is poorly accessible or insufficient for cell isolation, RPC expansion is inefficient, and optimal culture conditions are undefined. In the setting of chronic injury, therapy with RPCs that are committed to the generation of nephron cells is likely to be ideal for achieving clinically relevant beneficial effects. Furthermore, use of patient-derived RPCs, from either tissue or urine, could offer an autologous CKD therapy that does not require immunosuppression. Testing the effect of RPCs in a model of CKD that is characterized by nephron loss, such as the 5/6 nephrectomy model, 19 would determine the feasibility of this approach, as would comparative analysis of the effects of adult and fetal RPCs.
Outcomes of cell therapy might also depend on the modality of cell delivery. Cells that are injected intravenously can become trapped in the lungs and liver and release paracrine factors from these sites. 94 Cells that are delivered intravenously or intra-arterially also need to cross two basement membranes to reach the tubular compartment. This delivery route seems to be possible in acute injury, when those barriers are partly damaged, but in chronic injury, intraparenchymal application might be necessary to ensure that the injected cells localize to the nephron. Indeed, intraparenchymal delivery has been used to administer RPCs or differentiated tubular cells in mouse models of CKD (Tables 2 and 3 ). This route of administration has the additional advantages of requiring few cells and avoiding cell dispersion in off-target organs. However, intraparenchymal delivery might be associated with adverse events, such as local necrosis, thrombosis and a limited distribution of the cells within the kidney.
Cell therapy with adult renal-derived cells
A number of studies have demonstrated that administering adult differentiated cell populations that have been isolated from normal kidneys has a therapeutic effect in renal injury. In a rat model of chronic renal damage, injection of cells from human renal cultures that were enriched with erythropoietin-positive cells improved renal function and reduced renal fibrosis and inflammation, whereas injection of erythropoietin-depleted cells did not. 95 However, cells survived for <12 weeks, suggesting that their effect was the result of a rapid paracrine mechanism. Another study suggested that a renal cell population enriched with tubular cells has a therapeutic effect. 96 In mice with established chronic kidney injury, intraparenchymal injection of isolated and subsequently cultured epithelial cells improved renal function, extended survival and reduced the severity of kidney tissue pathology. This epithelial cell subpopulation consisted mainly of cells from the tubule and collecting duct, and was depleted of glomerular, vascular and erythropoietin-producing cells. Similarly, intraparenchymal injection of cells from a population of rat epithelial cells that was enriched with tubular cells promoted regeneration in diabetic rats and stabilized disease progression for up to 1 year after treatment. 97 The proposed mechanism of action of the intraparenchymal injected renal cells in CKD was activation (after 3-6 weeks) of several genes, including the pluripotencyassociated gene SOX2 and the RPC marker gene CD24, which are involved in a regenerative response. 98 These data support the proposal that differentiated cells have regenerative capacity. 26 
Conclusions and perspectives
The molecular profiles of fetal cells that form the nephrons have been characterized, but the nature of the cells that are involved in kidney homeostasis and regeneration is unclear. Further studies are required to understand the mechanisms involved in the activation of these cells. Adult human RPCs that are isolated from different nephron compartments seem to exhibit progenitorlike properties and have a therapeutic effect in animal models of acute and chronic renal damage. 38, 43, 44, 61, 87 In preclinical models of acute injury, the therapeutic effect of RPCs seems to be comparable to that of MSCs. 87 Therapy with MSCs would benefit from an increase in the number of readily-available MSC sources and from reducing the associated difficulties of immune compatibility (Figure 2) .
Although successful engraftment of adult RPCs within renal tissue has been achieved in animal models of acute injury, the effect of these cells in a model of CKD with nephron loss must be established. Adult RPCs could offer an ideal therapy for patients with renal failure, as they are committed to the kidney cell progeny and would therefore obviate the development of inappropriate cell types. However, RPCs can only be obtained from limited sources, their life span is short, they become senescent over time and they have restricted nephrogenic potential.
Fetal-like RPCs that have nephrogenic potential seem to be the ideal cell type for cell-based therapy in CKD. In vitro generation of renal progenitors by differentiation of iPSCs could overcome ethical issues and produce autologous tissue. However, this approach is currently limited because the process requires long and complex differentiation passages and the resulting progenitor cells do not proliferate in culture. Direct reprogramming of renal cells to produce RPCs could overcome this issue and generate expandable progenitor cells, but no longterm culture system has proven to be capable of maintaining adequate expansion of human adult progenitor cells over an extended period.
Adult renal cells also seem to have unexpected therapeutic potential, and could be considered as a simple therapy for kidney regeneration. Future work should aim to increase our understanding of the nature of these cells, including the whether the population includes RPCs, and of their mechanism of action.
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